Business context and reporting period
Sono-Tek Corporation designs, manufactures and sells ultrasonic spray-coating systems and related equipment for electronics, advanced energy, medical devices, glass, textiles and food applications. This Form 10-K covers the fiscal year ended February 28, 2015 (FY2015), compared with FY2014. It does not provide a separate fourth-quarter results summary; the supplied filing text is annual. The consolidated financial statements received an unqualified audit opinion.
Key financial metrics
| Metric | FY2015 | FY2014 | Change |
|---|---|---|---|
| Consolidated net sales | $10.849 million | $10.279 million | +5.6% |
| Gross profit | $5.215 million | $4.733 million | +10.2% |
| Gross margin | 48.1% | 46.0% | +2.1 percentage points |
| Operating income | $850,000 | $719,000 | +18.3% |
| Net income | $606,000 | $484,000 | +25.1% |
| Diluted earnings per share | $0.04 | $0.03 | Increased |
| Cash provided by operations | $924,000 | $1.668 million | Down $744,000 |
| Cash and cash equivalents | $2.563 million | $3.232 million | Down $669,000 |
| Marketable securities | $1.652 million | $631,000 | Up $1.022 million |
| Total debt | $1.478 million | $1.671 million | Down $193,000 |
| Working capital / current ratio | $5.271 million / 3.5:1 | $4.753 million / 3.6:1 | Working capital up $518,000 |
Consolidated gross margin was approximately 48.1%; operating margin was 7.8% and net margin was 5.6%. The company had no borrowings on its $750,000 revolving credit line at year-end and reported $20,542 outstanding under its equipment loan. Its $1.457 million mortgage note bears 4.15% interest. The filing also describes a separate $250,000 equipment purchase facility.
Material changes versus FY2014
- Management’s ultrasonic-spraying segment reported sales of $10.758 million, up 5.4%, and gross profit of $5.124 million, up 10%. It attributed the improved margin to higher sales of stent coaters, XYZ coating units and fluxers. These segment figures differ from consolidated totals, which include real-estate operations and eliminations.
- Sales increased for nozzles and generators, XYZ units, fluxers and stent-coating units; WideTrack units, solder-recovery systems and servo units declined.
- Foreign sales fell 22% to $5.018 million, or 47% of revenue versus 63%. Far East sales declined 35% to $2.147 million; Western Europe sales rose 14% to $2.069 million. Management noted FY2014 included about $800,000 of WideTrack equipment sales to the Far East.
- Research and product-development expense rose 15% to $1.016 million; marketing and selling expense increased 10% to $2.153 million. Management cited higher engineering costs, commissions, travel and sales salaries.
- Operating cash flow fell, principally alongside increases in accounts receivable ($180,000) and inventory ($484,000). Investing used $1.401 million, including $1.022 million for marketable securities and $357,000 for equipment and improvements.
- Interest expense decreased to $65,000 from $110,000, which management attributed to the December 2013 industrial-park refinancing. Income-tax expense increased to $219,000 from $130,000.
Outlook, risks and other notable items
No quantitative revenue or earnings guidance is provided. Management described its expanded products, markets and geographic reach as a foundation for future sales growth and improved profitability, while noting that growth in certain markets depends on customers prioritizing capital investment. It highlighted textile opportunities and food-industry applications, but did not quantify expected demand or timing.
Risks identified in the filing include general economic conditions; competitive, regulatory and technological changes; timely development and market acceptance of new products; financing adequacy; capacity additions; patent enforcement; and the ability to grow sales and sustain profitability. International sales remain material, with foreign markets accounting for 47% of revenue. One customer represented 7% of FY2015 sales; two customers represented 25% of year-end receivables. The filing states there were no material commitments or contingencies, no legal proceedings and no off-balance-sheet arrangements. Bank guarantees totaling $43,518 were collateralized by cash and were due to expire at various dates in 2015.
Management reported effective disclosure controls and internal control over financial reporting as of year-end. The company paid no cash dividends and said it intended to retain earnings. The board amended the CEO’s and president’s change-in-control agreements in August 2014, increasing specified severance from one to two years of base and bonus compensation.
Important facts for investors to verify
- Reconcile the MD&A’s ultrasonic-segment revenue and gross profit with the higher consolidated statement totals; confirm the effects of real-estate activity and intercompany eliminations.
- Assess whether the decline in foreign sales, particularly in the Far East, is temporary or signals sustained demand weakness; verify the sales pipeline and customer capital-spending plans.
- Track inventory growth and reserves, receivable collections, and whether operating cash flow recovers after its year-over-year decline.
- Review debt maturities, mortgage terms, annual line-of-credit paydown requirements and the status of the 2015-expiring customer guarantees.
- Evaluate execution and commercial adoption of new products and applications, including the timing and economics of textile and food opportunities.
- Confirm subsequent developments and later-period results: this filing’s stated outlook is qualitative, and the filing text provides no separate Q4 figures.